1. Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial. Issue 6 (18th December 2019) Authors: Papakonstantinou, Antroula; Matikas, Alexios; Bengtsson, Nils Olof; Malmström, Per; Hedayati, Elham; Steger, Guenther; Untch, Michael; Hübbert, Laila; Johansson, Hemming; Hellström, Mats; Gnant, Michael; Loibl, Sibylle; Greil, Richard; Moebus, Volker; Foukakis, Theodoros; Bergh, Jonas Journal: Cancer Issue: Volume 126:Issue 6(2020) Page Start: 1175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. (2nd January 2020) Authors: Papakonstantinou, Antroula; Hedayati, Elham; Hellström, Mats; Johansson, Hemming; Gnant, Michael; Steger, Günther; Greil, Richard; Untch, Michael; Moebus, Volker; Loibl, Sibylle; Foukakis, Theodoros; Bergh, Jonas; Matikas, Alexios Journal: Acta oncologica Issue: Volume 59:Number 1(2020) Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗